Therapeutic Areas Hematology / Oncology

Hematology / Oncology

Hematology and oncology are growing areas of research with several new and innovative products in development over the last several years. CTI has led projects across the spectrum of hematology and oncology research including complex and rare diseases. Our expertise includes a Medical Affairs team with a background in hematological malignancies and stem cell transplantation as well as an oncologist, all of which work closely with the rest of our organization so that project teams are familiar with these often complex and critically ill patients. We have managed projects involving adult, pediatric, and neonate populations on clinical trials, educational programs, and regulatory consulting. Past and ongoing trials have ranged from small first-in-human trials to large expanded access programs (EAPs). We have been involved in the development of numerous products in these areas, including recently approved Voraxaze®. We routinely attend industry meetings focused on hematology and oncology, including the American Society for Hematology annual meetings (ASH).

Immuno-oncology is the frontier of personalize medicine, and it is an area CTI excels in. Approximately 30% of CTI's most recent programs are in oncology and cell therapy, and over half of our recent projects are deeply rooted in immunological indications. Our approach has stayed true to our therapeutic focus and clinical trial expertise. We focus in complex and critically ill patient populations, bringing a huge reservoir of immunology and cellular therapy expertise to these programs.

Harald von Eick, Msc
Managing Director, Europe
With more than 30 years of clinical and industry experience, Harald has a significant background in oncology, expertise in managing multinational trials in complex patient populations, and provides overall leadership of CTI European operations.

Harald Von Eick

Some of our adult and pediatric experience includes:

  • B cell lymphoma
  • Beta-Thalassemia
  • Bladder cancer
  • Coagulation (bleeding disorders)
  • Graft versus host disease (GVHD)
  • Head-and-neck cancer
  • Hematological malignancies
  • Hemochromatosis
  • Heparin-induced thrombocytopenia (HIT)
  • Hodgkin’s disease/lymphoma
  • Leukemia
  • Lymphoma
  • Melanoma
  • Methotrexate toxicity
  • Myeloma
  • Neuro-oncology
  • Non-Hodgkin’s lymphoma
  • Pancreatic cancer
  • Pediatric malignancies
  • Post-surgical bleeding
  • Rare cancers
  • Sarcoma
  • Solid tumors
  • Stem cell transplant
  • Wound healing

We offer our sponsors:

Request Information

Icon Contact Small Retina

CTI is ready to help with your next drug development project

Contact Us